Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column-A prospective, multicenter, randomized, within-patient and parallel-group comparative study to evaluate efficacy and safety

Tsutomu Yoshikawa, Akiyasu Baba, Makoto Akaishi, Yasuhisa Wakabayashi, Toshiaki Monkawa, Masafumi Kitakaze, Tohru Izumi, Hitonobu Tomoike

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Over the past few decades, several cardiac autoantibodies have been reported in sera from patients with dilated cardiomyopathy (DCM). Immunoadsorption (IA) therapy is one of the therapeutic tools to remove such autoantibodies. The objective of this study was to investigate functional effects of IA therapy using a tryptophan column in severe DCM patients. Of 49 patients enrolled, 44 were randomized from 10 sites in Japan. IA therapy was conducted in 40 patients with DCM (refractory to standard therapy for heart failure, New York Heart Association [NYHA] class III/IV, left ventricular ejection fraction [LVEF]

Original languageEnglish
JournalJournal of Clinical Apheresis
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Dilated Cardiomyopathy
Tryptophan
Safety
Autoantibodies
Therapeutics
Stroke Volume
Japan
Heart Failure
Serum

Keywords

  • Antibodies
  • Dilated cardiomyopathy
  • Heart failure
  • Immune system

ASJC Scopus subject areas

  • Hematology

Cite this

Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column-A prospective, multicenter, randomized, within-patient and parallel-group comparative study to evaluate efficacy and safety. / Yoshikawa, Tsutomu; Baba, Akiyasu; Akaishi, Makoto; Wakabayashi, Yasuhisa; Monkawa, Toshiaki; Kitakaze, Masafumi; Izumi, Tohru; Tomoike, Hitonobu.

In: Journal of Clinical Apheresis, 2016.

Research output: Contribution to journalArticle

@article{d20569d0dde04a5283357f61bebed5b5,
title = "Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column-A prospective, multicenter, randomized, within-patient and parallel-group comparative study to evaluate efficacy and safety",
abstract = "Over the past few decades, several cardiac autoantibodies have been reported in sera from patients with dilated cardiomyopathy (DCM). Immunoadsorption (IA) therapy is one of the therapeutic tools to remove such autoantibodies. The objective of this study was to investigate functional effects of IA therapy using a tryptophan column in severe DCM patients. Of 49 patients enrolled, 44 were randomized from 10 sites in Japan. IA therapy was conducted in 40 patients with DCM (refractory to standard therapy for heart failure, New York Heart Association [NYHA] class III/IV, left ventricular ejection fraction [LVEF]",
keywords = "Antibodies, Dilated cardiomyopathy, Heart failure, Immune system",
author = "Tsutomu Yoshikawa and Akiyasu Baba and Makoto Akaishi and Yasuhisa Wakabayashi and Toshiaki Monkawa and Masafumi Kitakaze and Tohru Izumi and Hitonobu Tomoike",
year = "2016",
doi = "10.1002/jca.21446",
language = "English",
journal = "Journal of Clinical Apheresis",
issn = "0733-2459",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column-A prospective, multicenter, randomized, within-patient and parallel-group comparative study to evaluate efficacy and safety

AU - Yoshikawa, Tsutomu

AU - Baba, Akiyasu

AU - Akaishi, Makoto

AU - Wakabayashi, Yasuhisa

AU - Monkawa, Toshiaki

AU - Kitakaze, Masafumi

AU - Izumi, Tohru

AU - Tomoike, Hitonobu

PY - 2016

Y1 - 2016

N2 - Over the past few decades, several cardiac autoantibodies have been reported in sera from patients with dilated cardiomyopathy (DCM). Immunoadsorption (IA) therapy is one of the therapeutic tools to remove such autoantibodies. The objective of this study was to investigate functional effects of IA therapy using a tryptophan column in severe DCM patients. Of 49 patients enrolled, 44 were randomized from 10 sites in Japan. IA therapy was conducted in 40 patients with DCM (refractory to standard therapy for heart failure, New York Heart Association [NYHA] class III/IV, left ventricular ejection fraction [LVEF]

AB - Over the past few decades, several cardiac autoantibodies have been reported in sera from patients with dilated cardiomyopathy (DCM). Immunoadsorption (IA) therapy is one of the therapeutic tools to remove such autoantibodies. The objective of this study was to investigate functional effects of IA therapy using a tryptophan column in severe DCM patients. Of 49 patients enrolled, 44 were randomized from 10 sites in Japan. IA therapy was conducted in 40 patients with DCM (refractory to standard therapy for heart failure, New York Heart Association [NYHA] class III/IV, left ventricular ejection fraction [LVEF]

KW - Antibodies

KW - Dilated cardiomyopathy

KW - Heart failure

KW - Immune system

UR - http://www.scopus.com/inward/record.url?scp=84958191359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958191359&partnerID=8YFLogxK

U2 - 10.1002/jca.21446

DO - 10.1002/jca.21446

M3 - Article

C2 - 26801483

AN - SCOPUS:84958191359

JO - Journal of Clinical Apheresis

JF - Journal of Clinical Apheresis

SN - 0733-2459

ER -